PETALING JAYA: Despite the key risks of lower-than-expected sales volumes and depreciation of the ringgit against the US dollar, Duopharma Biotech Bhd
is on a strong footing to rake in steady revenue growth by next year.
The attributing factors which would support the pharmaceutical company’s revenue stream include the Approved Product Purchase List (APPL) tender and higher healthcare budget allocations for next year.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
